Shantha Biotechnics, an affiliate of Sanofi Pasteur, has received approval from the World Health Organisation (WHO) for Shanchol, its oral cholera vaccine.
The approval is for use at temperatures as high as 40°C for up to 14 days, immediately prior to administration, among others.
The approval is of significance to regions where the vaccine is used, including India, as it eliminates the challenges of maintaining the vaccine cold chain (between plus 2°C and plus 8°C to maintain vaccine potency) during transport..
“The WHO’s approval will help us make Shanchol available to populations living in remote, hard-to-reach areas of India and other parts of the world, especially ones with erratic electricity supply,” Mahesh Bhalgat, Executive Director and Chief Operating Officer, Shantha Biotechnics, said in a release issued here on Monday.
The WHO approval for use of Shanchol in controlled temperature chain (CTC) was granted after a review of its stability data.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.